You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Lithuania

Mar 2011

Price: $2,400

About this Report

About this Report

Delivery method: instant download
Report format: PDF doc_pdf.png (download a sample)
Market statistics: Excel workbook doc_excel_table.png (download a sample)

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Lithuania with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Lithuania, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Lithuania for free:

The Consumer Health in Lithuania market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Lithuania?
  • What are the major brands in Lithuania?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Sample Analysis

EXECUTIVE SUMMARY

Consumer health sales continue to slide in the economic downturn

After recording the first contraction of sales in more than a decade in 2009, consumer health continued to shrink in 2010. Companies struggled to adapt to changed consumption patterns. Calculated, rational consumption and bargain-hunting replaced the lavish spending seen during the pre-economic crisis, a trend intensified by continuous special offers from retailers. Although the signs of stabilisation were visible in 2010, especially in the most essential categories, companies were still more concerned about survival rather than profitability.

The intervention of politicians forces companies to adjust

The Ministry of Health was active in 2010, setting the upper limits for consumer health profits so that the products would become more affordable to consumers on strict budgets. It also ensured that pharmacists recommended the cheapest remedy to consumers. As of 2010, little impact was noticeable by consumers. The prices of the cheapest consumer health products were raised while the most expensive products became cheaper. As for price transparency, little was achieved apart from confusion amongst industry players. Consumers are not educated enough to make their own decision and rely on the advice of the pharmacist.

Multinationals gain share at the expense of local companies

While domestic companies performed well during the boom years of 2004-2008 foreign companies and their subsidiaries are projected to be the ultimate winners after the economic crisis subsides. Because of coherent marketing strategies and strong financial backing to withstand the economic crisis, foreign firms did not engage in price wars, which prevented their products from losing brand equity. This will lead to better results in the future. There were few strong pharmaceuticals brands created during the boom years of 2004-2008 and as a result brand loyalty was replaced by price loyalty in times of economic hardship. Advertising remained vital to strong sales, but it was the price rather than the attractive packaging that determined the winner in 2010.

Chemists/pharmacies remain the dominant distribution channel

The majority of consumer health sales were through chemists/pharmacies in 2010. While the number of consumer health outlets in Lithuania was stable until 2010, they underwent a process of concentration in this year. Four players had the majority of sales and competed for share by offering price discounts. To do this and still operate profitably, chemists/pharmacies focused on the improvement of their operations. Poorly-performing brands were removed from the shelves, which encouraged higher turnover of stock.

Sluggish growth expected over the forecast period

Once the economic crisis is over, its impact will remain noticeable in the forecast period. Spending on consumer health will remain rational, with consumers requiring more value for less money. Although the trend towards self-medication is expected to prevail, factors that decrease the market size will abound: profits of industry players will be scrutinised by politicians, while the emergence of private label products will threaten the average unit price. Chemists/pharmacies will benefit from centralised operations, which will be better for consumers but worse for wholesalers and manufacturers, as their bargaining power will be weakened.

Table of Contents

Table of Contents

Consumer Health in Lithuania - Industry Overview

EXECUTIVE SUMMARY

Consumer health sales continue to slide in the economic downturn

The intervention of politicians forces companies to adjust

Multinationals gain share at the expense of local companies

Chemists/pharmacies remain the dominant distribution channel

Sluggish growth expected over the forecast period

KEY TRENDS AND DEVELOPMENTS

Retailing of consumer health continues to concentrate

Private label emerges

Heavy discounting is used by companies to boost sales

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2005-2010
  • Table 2 Life Expectancy at Birth 2005-2010

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2005-2010
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2005-2010
  • Table 5 Consumer Health Company Shares 2006-2010
  • Table 6 Consumer Health Brand Shares 2007-2010
  • Table 7 Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
  • Table 8 Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
  • Table 9 Forecast Sales of Consumer Health by Category: Value 2010-2015
  • Table 10 Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

APPENDIX

OTC Registration and Classification

Vitamins and dietary supplements registration and classification

Self-medication/self-care and preventative medicine

Switches

  • Summary 1 OTC Healthcare Switches 2008-2010

DEFINITIONS

  • Summary 2 Research Sources

Consumer Health in Lithuania - Company Profiles

Sanitas AB - Consumer Health - Lithuania

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 5 Sanitas AB Production Statistics 2009

COMPETITIVE POSITIONING

  • Summary 6 Sanitas AB Competitive Position 2010

Sicor Biotech UAB - Consumer Health - Lithuania

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

Valentis UAB - Consumer Health - Lithuania

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Table 11 Summary3 Valentis UAB: Competitive Position 2010

Adult Mouth Care in Lithuania - Category Analysis

HEADLINES

TRENDS

  • Adult mouth care products withstood the economic crisis much better than the rest of consumer health. Although the standard unit price of a typical mouth rinse is above LTL10, mouth care products are indispensable to Lithuanians. A significant portion of mouth care sales are generated by the elderly population who have dental prosthesis. Adult mouth care suffered less from down-trading in 2010 because Lithuanians follow the advice of dentists closely and do not change products they are used to.

SWITCHES

COMPETITIVE LANDSCAPE

  • Pfizer Inc remains the leader of a fragmented category in 2010. Thanks to its leading brand Hexoral, the company has a 24% value share, down by two percentage points from 2009. CSC Pharmaceuticals Handels GmbH, despite suffering significant loss of sales, was ranked second because of strong sales of its Tantum Verde brand.

PROSPECTS

  • Adult mouth care was stable over the review period, with no excessive movements up or down. The trend is expected to continue over the forecast period as sales will gradually increase, thanks to stable demand, the necessity of the products and recovering spending power of consumers.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2005-2010
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2005-2010
  • Table 14 Adult Mouth Care Company Shares 2006-2010
  • Table 15 Adult Mouth Care Brand Shares 2007-2010
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2010-2015
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2010-2015

Analgesics in Lithuania - Category Analysis

HEADLINES

TRENDS

  • After registering a 10% value decline in 2009, sales of analgesics continued to falter albeit at a slower pace. Despite two consecutive years of decline, influenced by the price wars between manufacturers and retailers, analgesics remained the third largest of all OTC in terms of market size. Lithuanians continued to stock up on analgesics, because they feel that once the pain becomes unbearable there is no time to visit the pharmacy. Leaflets from chemists/pharmacies that had information on discounted prices were thoroughly studied and products were purchased at discounted prices, which resulted in the decline of analgesics by 6% from 2009.

SWITCHES

COMPETITIVE LANDSCAPE

  • Due to its size and potential earnings, analgesics continued to have a large number of brands, ranging from cheap generics to more expensive branded products. The economic crisis intensified the competition between companies and those which had cheaper medicines in their portfolios performed better.

PROSPECTS

  • Analgesics is projected to remain lucrative for companies in the forecast period. Several factors will influence growth. The ageing population means that increasing numbers of Lithuanians will suffer from age-related diseases that will cause joint, muscle or head aches. Lifestyles are becoming more stressful, which in turn will force younger consumers to seek relief from consumer health products. Most of the issues will be addressed without seeing a doctor as such visits are very time-consuming and have large associated financial costs.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2005-2010
  • Table 19 Sales of Analgesics by Category: % Value Growth 2005-2010
  • Table 20 Analgesics Company Shares 2006-2010
  • Table 21 Analgesics Brand Shares 2007-2010
  • Table 22 Forecast Sales of Analgesics by Category: Value 2010-2015
  • Table 23 Forecast Sales of Analgesics by Category: % Value Growth 2010-2015

Calming and Sleeping in Lithuania - Category Analysis

HEADLINES

TRENDS

  • The demand for calming and sleeping products remained stable in 2010. The difficult situation in the labour market forced workers to work longer hours and, as a result, a number of Lithuanians suffered from anxiety, stress and insomnia. While some turned to yoga or other recreational methods, calming and sleeping products remained the primary option to deal with the problems. The majority of products were herbal/traditional calming and sleeping products, which improved the image of these remedies and did not deter customers who were not willing to consume synthetic products to treat mild symptoms.

SWITCHES

COMPETITIVE LANDSCAPE

  • Valentis UAB, a domestic company, was the leader in 2010 with a 36% value share. The leading position of the company was due to consumer preference for domestic and herbal production as well as good availability. Two brands had the majority share of the company's sales. Tinc Valerianae has been in the market for years and has gained the trust of consumers. Rameval, another remedy, is gradually increasing share over the years and is currently the best selling calming and sleeping product in the market. Both Tinc Valerianae and Rameval are sold at a competitive price, which was important in the economic climate of 2010.

PROSPECTS

  • Calming and sleeping products is expected to remain popular with consumers as stress and anxiety will remain common amongst Lithuanians. While the usage of calming and sleeping products was stigmatised in the past, consumers no longer neglect their need for such medicine.

CATEGORY DATA

  • Table 24 Sales of Calming and Sleeping: Value 2005-2010
  • Table 25 Sales of Calming and Sleeping: % Value Growth 2005-2010
  • Table 26 Calming and Sleeping Company Shares 2006-2010
  • Table 27 Calming and Sleeping Brand Shares 2007-2010
  • Table 28 Forecast Sales of Calming and Sleeping: Value 2010-2015
  • Table 29 Forecast Sales of Calming and Sleeping: % Value Growth 2010-2015

Cough, Cold and Allergy (Hay Fever) Remedies in Lithuania - Category Analysis

HEADLINES

TRENDS

  • Cough, cold and allergy (hay fever) remedies declined by -4% in 2010 which was slower than the 2009 rate of -10%. The 2009 decline occurred despite the panic concerning swine flu, when less educated consumers purchased remedies designed to treat colds. The continuing decline was due to price discounting that companies and chemists/pharmacies initiated to attract price-conscious consumers. Cough, cold and allergy (hay fever) remedies is very competitive, with a large number of brands vying for sales and little brand loyalty from consumers.

SWITCHES

COMPETITIVE LANDSCAPE

  • There was a new leading brand in 2010, Theraflu, by Novartis AG with an 8% value share. It narrowly outperformed its closest rival, Gripex by US Pharmacia Sp zoo, despite its higher price. The perceived differences between the two brands, as well as the wider range of formats of Theraflu were major factors in determining the leader. Gelomyrtol, a combination product offered by Pohl-Boskamp GmbH & Co was the third best-selling brand with sales of LTL4 million and a 7% value share.

PROSPECTS

  • Cough, cold and allergy (hay fever) remedies sales are highly seasonal and therefore hard to predict. In the winter months in general and during flu seasons in particular consumers change their attitudes and are less price conscious. The management of stock for cough, cold and allergy (hay fever) remedies becomes complicated for chemists/pharmacies, which can lead to product shortages for some companies and lucrative profits opportunities for others. This is unpopular with government officials.

CATEGORY DATA

  • Table 30 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 32 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares 2006-2010
  • Table 33 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares 2007-2010
  • Table 34 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
  • Table 35 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Digestive Remedies in Lithuania - Category Analysis

HEADLINES

TRENDS

  • While sales declined for the second consecutive year, the yearly spending of LTL6 per capita, one of the highest of all categories, indicates that Lithuanians were still trying to treat digestive tract problems with digestive remedies. Poor nutritional habits were the main reason for demand with a high intake of fat and not enough fruit and vegetables consumed.

SWITCHES

COMPETITIVE LANDSCAPE

  • Digestive remedies has a clear leader in sales. Despite the loss of one percentage point in 2010, Menarini Industrie Farmaceutiche Riunite Srl held a dominant 59% of digestive remedies with sales of LTL12 million in 2010. As in the review period, advertising was the major reason for success. Its digestive enzyme brand Mezym was once again the most popular consumer health brand available and accounted for a third of all digestive remedies in value terms. Menarini Industrie Farmaceutiche Riunite Srl also has the second and fourth best-selling products in digestive remedies, Raniberl and Espumisan, with a 16% and 9% value share respectively due to heavy promotional activities.

PROSPECTS

  • The growth of digestive remedies sales is expected to be lower than that seen between 2000-2007, when consumers bought a large amount of products without a specific reason. Advertising also encouraged them to buy expensive products. While the demand for digestive remedies will remain stable or even increase, purchasing decisions will be rationalised. Smaller packages, an increasing share of generics, less influence from advertising and more attention to prices will define the consumption of digestive remedies in the forecast period.

CATEGORY DATA

  • Table 36 Sales of Digestive Remedies by Category: Value 2005-2010
  • Table 37 Sales of Digestive Remedies by Category: % Value Growth 2005-2010
  • Table 38 Digestive Remedies Company Shares 2006-2010
  • Table 39 Digestive Remedies Brand Shares 2007-2010
  • Table 40 Forecast Sales of Digestive Remedies by Category: Value 2010-2015
  • Table 41 Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015

Ear Care in Lithuania - Category Analysis

HEADLINES

TRENDS

  • Sales of ear care continued to decline in 2010. The major reason for the decline was the low purchasing power of consumers, who only bought ear care products when it became inevitable. The low value of ear care also made it less appealing to companies, which led to low levels of competition. There were therefore very few advertisements for ear care products.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires Biocodex SA was the leader in 2009 and strengthened its position after gaining one percentage point to reach a value share of 45% in 2010. Although the company has only one brand in the market, Otipax is well known to customers and is popular because of its attractive price. The second largest player in 2010 was ICN Pharmaceutical Inc. It had a 38% value share with its Otinum brand, which was the cheapest in ear care in 2010.

PROSPECTS

  • Ear care is not expected to register a strong growth over the forecast period as increased demand for the products is not expected. The majority of the gains are expected to come from rising unit prices, which are only possible if the economy recovers.

CATEGORY DATA

  • Table 42 Sales of Ear Care: Value 2005-2010
  • Table 43 Sales of Ear Care: % Value Growth 2005-2010
  • Table 44 Ear Care Company Shares 2006-2010
  • Table 45 Ear Care Brand Shares 2007-2010
  • Table 46 Forecast Sales of Ear Care: Value 2010-2015
  • Table 47 Forecast Sales of Ear Care: % Value Growth 2010-2015

Emergency Contraception in Lithuania - Category Analysis

HEADLINES

TRENDS

  • Following the switch from Rx to OTC in April 2009, large sums were assigned to promote the arrival of emergency contraception to consumer health. Magazines and internet sites that targeted young women as the core audience were targeted with advertisements. However, the results were poor. In 2010 sales contracted by -3%, which suggests that the demand for emergency contraception stabilised at 13,000 packages a year.

COMPETITIVE LANDSCAPE

  • There is no competition in emergency contraception as Richter Gedeon Nyrt remains the only company. Its Escapelle brand was assigned a larger marketing budget and as a result is ahead of the other Richter Gedeon Nyrt brand, Postinor-2 in terms of sales. Another reason for the disparity of sales of equally priced brands is the ease of use. Postinor-2 package contains two pills that have to be consumed, when Escapelle has only one pill.

PROSPECTS

  • Emergency contraception is projected to increase by constant value CAGR of 1% over the forecast period to reach LTL1 million by 2010. More awareness about OTC emergency contraception will be the driving force of growth. The growth base is still very low.

CATEGORY DATA

  • Table 48 Sales of Emergency Contraception: Value 2009-2010
  • Table 49 Sales of Emergency Contraception: % Value Growth 2009-2010
  • Table 50 Emergency Contraception Company Shares 2006-2010
  • Table 51 Emergency Contraception Brand Shares 2007-2010
  • Table 52 Forecast Sales of Emergency Contraception: Value 2010-2015
  • Table 53 Forecast Sales of Emergency Contraception: % Value Growth 2010-2015

Eye Care in Lithuania - Category Analysis

HEADLINES

TRENDS

  • Despite the economic downturn and decreased purchasing power, consumers were not willing to cut spending on eye care products. The resistance of eye care stems from the necessity for eye care products. An increasing number of Lithuanians spent long hours working with computers, and air conditioning and heating during the winter also had a negative effect on the condition of eyes.

SWITCHES

COMPETITIVE LANDSCAPE

  • Alcon-Couvreur SA NV overtook Unimed Pharma to lead in 2010. Strong sales of its Tears Naturale brand was a result of lower prices than those of competing products, which was popular with budget-conscious customers. The importance of the price is illustrated by the fact that Hypromeloza P, a brand of Unimed Pharma, is also among the cheapest of all brands.

PROSPECTS

  • Forecast growth is good in terms of the potential demand for eye care products. The ageing population and increasing time spent in front of computer screens will force consumers to seek remedies, mostly artificial tears. However, the affordability of such products will remain an issue. The poor economy and fragile social payments system means that only the most necessary purchases will be bought by elderly consumers.

CATEGORY DATA

  • Table 54 Sales of Eye Care by Category: Value 2005-2010
  • Table 55 Sales of Eye Care by Category: % Value Growth 2005-2010
  • Table 56 Standard Eye Care by Type: % Value Breakdown 2007-2010
  • Table 57 Eye Care Company Shares 2006-2010
  • Table 58 Eye Care Brand Shares 2007-2010
  • Table 59 Forecast Sales of Eye Care by Category: Value 2010-2015
  • Table 60 Forecast Sales of Eye Care by Category: % Value Growth 2010-2015

Herbal/Traditional Products in Lithuania - Category Analysis

HEADLINES

TRENDS

  • Herbal/traditional products was not immune to the prolonged slump in sales. The major reason for the poor performance of herbal/traditional products is that it continued to be considered less effective than standard remedies in 2010. With low spending income consumers were not willing to experiment and relied on the trusted and well-known standard remedies. Another reason for falling sales is that herbal/traditional products is more expensive than standard remedies, which further limits the incentives of consumers to purchase it.

COMPETITIVE LANDSCAPE

  • Local company Valentis UAB led herbal/traditional products in 2010. The company had a 9% share in 2010, up from 8% in 2009. The poor performance of herbal/traditional dietary supplements was the reason for the slow growth compared to Valentis' stronger positions in herbal/traditional calming and sleeping products and herbal/traditional cough, cold and allergy (hay fever) remedies, which were more resistant during the recession. The firm also benefited from the cheaper prices of its products compared to those of the competition.

PROSPECTS

  • The economic recession and subsequent shifts in consumer spending patterns had a negative effect on the development of herbal/traditional products. However, the outlook is bright for herbal/traditional products. The overall trend of naturalness will be noticeable in the rest of consumer health, which will lead to increasing awareness and demand for such products.

CATEGORY DATA

  • Table 61 Sales of Herbal/Traditional Products: Value 2005-2010
  • Table 62 Sales of Herbal/Traditional Products: % Value Growth 2005-2010
  • Table 63 Herbal/Traditional Products Company Shares 2006-2010
  • Table 64 Herbal/Traditional Products Brand Shares 2007-2010
  • Table 65 Forecast Sales of Herbal/Traditional Products: Value 2010-2015
  • Table 66 Forecast Sales of Herbal/Traditional Products: % Value Growth 2010-2015

Medicated Skin Care in Lithuania - Category Analysis

HEADLINES

TRENDS

  • Medicated skin care suffered significant losses since the economic crisis began in Lithuania. In addition to the declining spending power of consumers, it was affected by saturation. During the growth years of 2000-2007 medicated skin care products were purchased without any specific reason, as the line between medicated skin care products and simple cosmetic products was blurred. Lower purchasing power forced consumers to reconsider and in 2010 products were only bought when there were skin problems to treat. In cases where medicated skin care products were bought, consumers requested smaller packages and used them for longer.

SWITCHES

COMPETITIVE LANDSCAPE

  • Medicated skin care is very fragmented with different companies in leading positions within it. Spirig Pharma AG was the overall leader in 2010 with sales of LTL1 million, but its 8% value share shows that it did not dominate. Egis Slovakia spol sro and Hexal AG were second and third with respective shares of 7% and 6%, thanks to their leading brands Betadine and Acic creme.

PROSPECTS

  • Medicated skin care is not expected to return to pre-economic crisis levels because there will be no more excessive usage of medicated skin care products without a real reason to purchase. Instead, consumers will take a much more rational approach, which includes the thorough reading of product labels and comparison of prices of similar products. The advice of specialists, such as pharmacists and dermatologists, will also rise in value as Lithuanians will not want to spend on the wrong medicine

CATEGORY DATA

  • Table 67 Sales of Medicated Skin Care by Category: Value 2005-2010
  • Table 68 Sales of Medicated Skin Care by Category: % Value Growth 2005-2010
  • Table 69 Medicated Skin Care Company Shares by Value 2006-2010
  • Table 70 Medicated Skin Care Brand Shares 2007-2010
  • Table 71 Hair Loss Treatments Brand Shares 2007-2010
  • Table 72 Forecast Sales of Medicated Skin Care by Category: Value 2010-2015
  • Table 73 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2010-2015

NRT Smoking Cessation Aids in Lithuania - Category Analysis

HEADLINES

TRENDS

  • The increase of excise duties on tobacco products as a means to increase budget revenue presented the opportunity for NRT smoking cessation aids to increase sales. Smokers in Lithuania faced higher prices of cigarettes and other tobacco products in 2010 and some decided to stop smoking. However, the sales of NRT smoking cessation aids did not increase, because the market of just over 700 000 smokers is too small for large-scale advertising campaigns. Further declining spending power of consumers also had a negative effect on the performance of NRT smoking cessation aids.

SWITCHES

COMPETITIVE LANDSCAPE

  • Pfizer Inc maintained its leading position thanks to its Nicorette and Nicorette Gum brands in 2010. With combined sales of LTL1 million and a combined 53% value share it outsold GlaxoSmithKline Plc and its Niquitin brand. The leading position of Pfizer Inc was determined by its early entrance into NRT smoking cessation aids. Lower prices also favoured Pfizer’s products, because consumers are more price sensitive than they were during the review period.

PROSPECTS

  • The low sales in 2010 are expected to prevent companies, either those already in NRT smoking cessation aids or those considering entering, from launching products in the future. Even the increasing excise duties failed to deter smokers from their habit as a large number simply turned to the illegal market. Of those trying to quit, willpower is expected to remain the most common method. The opportunities for the sales of NRT smoking cessation aids will remain good as a large portion of smokers are still not familiar with the products or have a negative view towards the effectiveness of such remedies.

CATEGORY INDICATORS

  • Table 74 Number of Smokers by Gender 2005-2010

CATEGORY DATA

  • Table 75 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2010
  • Table 76 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2010
  • Table 77 NRT Gum Flavours: % Value Breakdown 2006-2010
  • Table 78 NRT Smoking Cessation Aids Company Shares 2006-2010
  • Table 79 NRT Smoking Cessation Aids Brand Shares 2007-2010
  • Table 80 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2010-2015
  • Table 81 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2010-2015

Sports Nutrition in Lithuania - Category Analysis

HEADLINES

TRENDS

  • Sports nutrition was one of the hardest hit of all consumer health once the country’s economy declined. Demand shrank substantially as there was a limited number of regular users of sports nutrition products, namely professional athletes. A larger proportion of consumers were those that used the products while exercising in gyms and wanted additional results. These consumers prioritised their spending which led to falling sales.

COMPETITIVE LANDSCAPE

  • Universal Nutrition Inc was the leader of the fragmented sports nutrition in 2010 with a 14% share. The company lost two percentage points from 2009 as competition intensified. The firm has a wide range of products in all categories and benefits greatly from their availability in gyms. The logos of Universal Nutrition Inc on the posters in gyms as well as the t-shirts of fitness instructors helps to increase sales. Another reason for the company’s success is the approval of professionals in internet forums, where the higher than average unit price is considered to be justified by superior quality.

PROSPECTS

  • The prospects of sports nutrition are not good because these products were the first to be removed from shopping baskets and are expected to be the last ones to return once the economic crisis is over. Although the demand for an athletic appearance will remain stable, Lithuanians will not be able to afford to pay the prices of sports nutrition products, which sometimes exceeds gym membership prices.

CATEGORY DATA

  • Summary 11 Sports Nutrition, category rankings 2010
  • Table 82 Sales of Sports Nutrition: Value 2005-2010
  • Table 83 Sales of Sports Nutrition: % Value Growth 2005-2010
  • Table 84 Sports Nutrition By Format: % Value Breakdown 2007-2010
  • Table 85 Sports Nutrition Company Shares 2006-2010
  • Table 86 Sports Nutrition Brand Shares 2007-2010
  • Table 87 Forecast Sales of Sports Nutrition: Value 2010-2015
  • Table 88 Forecast Sales of Sports Nutrition: % Value Growth 2010-2015

Vitamins and Dietary Supplements in Lithuania - Category Analysis

HEADLINES

TRENDS

  • As the country’s economy continued to deteriorate in 2010, consumers ceased to purchase vitamins and dietary supplements. Despite various attempts from manufacturers and pharmacists to increase sales (usually by offering discounts reaching as much as 40%) there was little interest in the products as consumers do not consider them vital to their health.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Aconitum UAB, a domestic company, remained the leader of vitamins and dietary supplements in 2010 with a value share of 9%, down by one percentage point from 2009. Biosola UAB, another local firm, was second. Both of these companies saw sales contracting in 2010 due to poor marketing. Once the purchasing power of consumers started to decline, both Aconitum UAB and Biosola UAB decreased their prices. Such practices were successful but the companies exhausted their financial reserves and could not keep the prices low any longer. Furthermore, there was no money to spend on advertising, which makes the products less appealing to customers.

PROSPECTS

  • Manufacturers of vitamins and dietary supplements believe the outlook is bright for them and point to the per capita consumption levels in western countries which is higher than those of Lithuania several times over. Several opposing forces will shape the progress of vitamins and dietary supplements. Poor nutrition habits and stressful lives, the ageing population and an increasing share of innovative and therefore more expensive vitamins and dietary supplements will lead to increased value sales. The unit prices of 2010 are unsustainable, and some smaller companies are expected to go cease trading over the forecast period. Those that survive the economic crisis will have to increase their prices.

CATEGORY DATA

  • Summary 12 Dietary Supplements: Brand Ranking by Positioning 2010
  • Table 89 Sales of Vitamins and Dietary Supplements by Category: Value 2005-2010
  • Table 90 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2005-2010
  • Table 91 Dietary Supplements by Positioning 2006-2010
  • Table 92 Vitamins and Dietary Supplements Company Shares 2006-2010
  • Table 93 Vitamins and Dietary Supplements Brand Shares 2007-2010
  • Table 94 Vitamins Brand Shares 2007-2010
  • Table 95 Dietary Supplements Brand Shares 2007-2010
  • Table 96 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2010-2015
  • Table 97 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2010-2015

Weight Management in Lithuania - Category Analysis

HEADLINES

TRENDS

  • Weight management products were badly affected by the economic crisis in 2010. It suffered when consumers reviewed their spending habits and changed their priorities. The dubious benefits of the products also had a negative effect on sales, as did the lack of advertising.

COMPETITIVE LANDSCAPE

  • The multinational Vitabiotics Ltd is the leader of weight management with a 24% share, up from 16% in 2009. The success is attributable to its Dietrim brand, a weight loss supplement known for its efficiency. With 17% share GlaxoSmithKline was second with all sales generated by its Alli brand.

PROSPECTS

  • Weight management has bright prospects as obesity levels are not expected to decrease over the forecast period. Despite efforts by officials including the removal of unhealthy food from all schools, sedentary lifestyles and poor nutrition will make more people obese. Companies will use this trend as consumers, especially women, will try to meet the beauty standards dictated by the media. While spending for weight management products was curbed during the economic crisis, it is expected to improve once consumer confidence returns to previous levels.

CATEGORY DATA

  • Table 98 Sales of Weight Management by Category: Value 2005-2010
  • Table 99 Sales of Weight Management by Category: % Value Growth 2005-2010
  • Table 100 Weight Management Company Shares 2006-2010
  • Table 101 Weight Management Brand Shares 2007-2010
  • Table 102 Forecast Sales of Weight Management by Category: Value 2010-2015
  • Table 103 Forecast Sales of Weight Management by Category: % Value Growth 2010-2015

Wound Care in Lithuania - Category Analysis

HEADLINES

TRENDS

  • Wound care was virtually untouched by the economic crisis. After the contraction of -3% in 2009, it once again produced satisfactory results, shrinking by -4% in 2010. The performance was a result of no alternatives to wound care products, which were vital to consumers. The laws making first aid kits in vehicles mandatory in Lithuania also acted as stabilising factor.

COMPETITIVE LANDSCAPE

  • Laboratoires Urgo remained the leader after registering sales of LTL1 million and accounting for a 30% value share. The wide range of products as well as good availability and favourable shelf positioning were the main reasons for success. Over the years consumers were made aware of the company’s products sold under the Urgo brand.

PROSPECTS

  • Wound care is expected to benefit from the revival of the economy as consumers will trade up to more innovative products. The majority of the sales will be generated by large multinationals which can afford the research budget for the development of such sophisticated products as sprayable bandages.

CATEGORY DATA

  • Table 104 Sales of Wound Care by Category: Value 2005-2010
  • Table 105 Sales of Wound Care by Category: % Value Growth 2005-2010
  • Table 106 Wound Care Company Shares 2006-2010
  • Table 107 Wound Care Brand Shares 2007-2010
  • Table 108 Forecast Sales of Wound Care by Category: Value 2010-2015
  • Table 109 Forecast Sales of Wound Care by Category: % Value Growth 2010-2015

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Acne Treatments
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Child-Specific Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
    • Vitamins and Dietary Supplements
      • Child-Specific Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
          • Non-Herbal Dietary Supplements
            • Calcium Supplements
            • Co-Enzyme Q10
            • Combination Non-Herbal Dietary Supplements
            • Eye Health Supplements
            • Fish Oils
              • Cod Liver Oil
              • Other Fish Oils
            • Glucosamine
            • Mineral Supplements
            • Omega-3-6-9 (Fish and Non-Fish)
            • Probiotic Supplements
            • Protein Powder
            • Royal Jelly
            • Sam-E
            • Other Non-Herbal Dietary Supplements
          • Tonics and Bottled Nutritive Drinks
          • Vitamins
            • Multivitamins
            • Single Vitamins
              • Vitamin A
              • Vitamin B
              • Vitamin C
              • Vitamin D
              • Vitamin E
              • Other Single Vitamins
        • Weight Management
          • Meal Replacement Slimming
          • OTC Obesity
          • Slimming Teas
          • Weight Loss Supplements
          • Other Slimming Products
        • Herbal/Traditional Products
          • Herbal/Traditional Analgesics
          • Herbal/Traditional Calming and Sleeping Products
          • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
          • Herbal/Traditional Digestive Remedies
          • Herbal/Traditional Medicated Skin Care
          • Herbal/Traditional Medicinal Teas
          • Herbal/Traditional Smoking Cessation Aids
          • Herbal/Traditional Child-Specific Dietary Supplements
          • Herbal/Traditional Dietary Supplements
          • Herbal/Traditional Tonics and Bottled Nutritive Drinks
        • Allergy Care
          • Allergy Eye Care
          • Antihistamines/Allergy Remedies (Systemic)
          • Child-Specific Allergy Remedies
          • Topical Allergy Remedies/Antihistamines
        • Child-Specific Consumer Health
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
          • Child-Specific Cough, Cold and Allergy Remedies
            • Child-Specific Allergy Remedies
            • Child-Specific Cough/Cold Remedies
          • Child-Specific Digestive Remedies
            • Child-Specific Diarrhoeal Remedies
            • Child-Specific Indigestion and Heartburn Remedies
            • Child-Specific Laxatives
            • Child-Specific Motion Sickness Remedies
          • Child-Specific Medicated Skin Care
          • Nappy (Diaper) Rash Treatments
          • Child-Specific Vitamins and Dietary Supplements

      Statistics Included

      Statistics Included

      For each category and subcategory you will receive the following data in Excel format:

      From Passport

      • Market sizes
      • Company shares
      • Brand shares
      • Distribution
      • Analysis by format
      • Analysis by positioning
      • Analysis by type
      • Herbal/traditional vs standard
      • Pricing

      Market size details:

      • Retail volume
      • Retail volume % growth
      • Retail volume per capita
      • Retail value retail selling price % growth
      • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price real (constant 2008) prices % growth
      • Retail value retail selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price % growth
      • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price real (constant 2008) prices % growth
      • Retail value manufacturer selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price nominal (current) prices % growth
      • Retail value retail selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price nominal (current) prices % growth
      • Retail value manufacturer selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY

      Methodology

      Methodology

      Global insight and local knowledge

      With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

      This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

      Industry specialists

      Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

      Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

      The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

      Country and regional analysts

      Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

      In-country research network

      To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

      Research Methodology

      Our research methods

      Each Euromonitor International industry report is based on a core set of research techniques:

      Desk research

      With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

      • National statistics offices governmental and official sources
      • National and international trade press
      • National and international trade associations
      • Industry study groups and other semi-official sources
      • Company financials and annual reports
      • Broker reports
      • Online databases
      • The financial, business and mainstream press

      Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

      Store checks

      Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

      • Place: We track products in all relevant channels, selective and mass, store and non-store
      • Product: What are innovations in products, pack sizes and formats?
      • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
      • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

      Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

      Trade survey

      Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

      Trade surveys allow us to:

      • Fill gaps in available published data per company
      • Generate a consensus view of the size, structure and strategic direction of the category
      • Access year-in-progress data where published sources are out of date
      • Evaluate the experts’ views on current trends and market developments

      In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

      Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

      Company analysis

      At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

      At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

      Forecasts

      Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

      Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

      Data validation

      All data is subjected to an exhaustive review process, at country, regional and global levels.

      The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

      Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

      Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

      Market analysis

      Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

      Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

      my pages

      Want to find out more about this report?

      RELATED

      Consumer Lifestyle

      Future Demographic

      Country Report